Status:
COMPLETED
A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study is being conducted to compare the efficacy of ABT-874 versus Methotrexate in subjects with moderate to severe plaque psoriasis.
Detailed Description
This study is only being conducted in the EU and Canada
Eligibility Criteria
Inclusion
- Diagnosis of Psoriasis for 6 MO.. BSA 10%, PASI 12 or above, PGA 3 or above
Exclusion
- Previous exposure to anti-IL 12
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
317 Patients enrolled
Trial Details
Trial ID
NCT00679731
Start Date
April 1 2008
End Date
November 1 2009
Last Update
January 29 2013
Active Locations (43)
Enter a location and click search to find clinical trials sorted by distance.
1
Site Reference ID/Investigator# 9904
Graz, Austria, 8036
2
Site Reference ID/Investigator# 11001
Vienna, Austria, 1090
3
Site Reference ID/Investigator# 12763
Vienna, Austria, A-1030
4
Site Reference ID/Investigator# 8022
Brussels, Belgium, 1200